The cell wall of M. tuberculosis is principally made of lipids and sugars, the glycolipids being located on the outer surface, and a few proteins being located at the internal base of the The Immunopathology of Tuberculosis, the Mode of Action of the Bacillus Calmette-Guérin, of the Tuberculin and of the Immunotherapy
IntroductIon
The incidence of tuberculosis (TB) peaked in Europe between the 18 th and 19 th centuries. The disease receded in the 20 th century after the end of World War II. This recession was attributed to the vaccination of the population worldwide starting in 1950 with the BCG and to the chemotreatment of symptomatic patients. The effect of better living conditions following the end of World War II was not considered. A resurgence of TB occurred in the West in the late 1980s, which appears irreversible. The existence since 1947 of a vaccine and of a simple chemotherapy induced the TB actors to ignore the dilemmas and paradoxes posed by the vaccination. At least a quarter of humanity is infected, [1] but only 5%-10% of these subclinical cases develop into a clinical illness. At the benign end of the spectrum, in pleural TB, healing may occur without treatment. A transient worsening of pulmonary tuberculous lesions may appear at any time during treatment. [2, 3] To explain these paradoxes and enigmas, I postulated in 1996 an immunodepression generated by the pathogen and also by the drugs used to combat its multiplication. [4] This review addresses the immunopathology of Mycobacterium tuberculosis, the action of the vaccine, the meaning of a positive tuberculin, and the advantages of an immunotherapy.
membrane. [5] Lipids and sugars are not known to induce a vigorous immune response. The various immunological responses elicited by a TB invasion, starting from the initial uptake to full-blown disease, were described in 1999. [6, 7] The first response is innate and addresses the mycobacterial whole cell. There is no oxidative burst and a poor uptake of the mycobacteria by immune-activated macrophages. Interleukin-6 is produced, which suppresses T-cell responses. The potential for an extension of the infection is there. The second response addresses the low-molecular-weight nonpeptide antigens that constitute 95% of the mycobacterial cell surface. The potential to control the infection by interferon-gamma and interleukin-2 is usually present in pediatric populations but may be dwarfed by the energy induced by interleukin-10, which inhibits the cytokines active in delayed-type hypersensitivity (DTH) reactions. In general, no symptoms are denoted during these two initial phases of infection. If the host is unable to eradicate the pathogen, he mounts an immune response against large molecular weight lipoarabinomannan (LAM) and mycolic acid, which are embedded in the mycobacterial cell wall. The LAM produced by the pathogen serves as a virulence factor, with inflammatory reactions.
The disorders induced by an overproduction of LAM characterize postprimary infections, namely an inhibition of production of interferon-gamma and a suppression of DTH reactivity. Some TB patients presenting for specific treatment show T-lymphocytopenia and have 10-fold fewer interleukin-2-responsive T-cells than do controls. These patients need external help under the form of a therapy. At that level of infection, the bacterium suppresses immune responses against protein antigens, and if left unaided, the patient will become chronically infected and eventually die. The fourth response is specific for peptide antigens that are located within the mycobacterium. This stage may be reached spontaneously by the patient or else is obtained by a successful specific treatment. The evolution of the disease is given in Tables 1 and 2 .
Phenotype variation of tuberculosis strains
A flow-through method for the detection of the TB pathogen was developed, based on the capture of the pathogen on a membrane, labeling of the bacilli with antibodies raised against the cells of avirulent TB strain H37Ra and putting the immobilized antibodies in evidence with gold-labeled protein-A. [8] The method tested in Brazil, India, Pakistan, Iran, and France gave results varying from negative (−) to strong positive (++++) with sputa and cerebro-spinal fluid (CRF) fluid that were positive by staining. Purified samples (Iran and France) did not fare better. A 100-fold increase in the bacterial load from 1.1 × 10 5 bacteria to 1.5 × 10 7 did not improve the outcome. The cause of this unexpected variable sensitivity ranging from very good to nil was the primary rabbit antibodies against avirulent H37Ra strain used to label the bacilli, which sometimes they failed to do so. Results are given in Table 3 . [12] and the failure of the BCG was noted in 1999. [13] 
Early evidence of inefficacy and infectiousness of Bacillus Calmette-Guerin
The attenuated live bacillus limited, in guinea pigs, the dissemination of inhaled TB bacilli toward the liver as well as their secondary dissemination toward the lung. However, this live vaccine provoked a general lymphatic disease that was claimed to heal spontaneously within 3 weeks. The vaccine lent no protection at all to monkeys at risk. Lignières showed in 1927 that the vaccine occasionally induced tuberculous meningitis instead of preventing it. [14] Calmette refused to take these observations into account [12] and vaccinated human newborns. The proof of efficacy of the vaccine in newborns was, according to Calmette, a reduction in general mortality of the vaccinees and the skin allergy the vaccine elicited. The statistician Greenwood observed in 1928 that the general infantile mortality, in the protected environment where the vaccinated children were confined, was 17% in 1922 and dropped to only 5.1% in 1926, when they were vaccinated, indicating that the reduction in mortality in the protected environment started well before the vaccination took place.
The value of the Bacillus Calmette-Guerin
After World War II, the UNICEF, pushed by the French pediatrician Debré, donated 3 million dollars to the WHO to eliminate the vaccine based on Mycobacterium chelonae, which gave entire satisfaction, and impose the BCG vaccination. [15] The risk of adverse reactions due to BCG, mentioned as early as 1977, [16] was declared in 1988 to be 10 times inferior [17] to the adverse reactions observed with the Danish strain Copenhagen, reported in a prospective study in 1993. [18] This 
Extent of unapparent tuberculosis infections
About a quarter of the world population is said infected by TB in an unapparent way. This claim is consolidated by a monitoring of the presence of antibodies of the immunoglobulin G (IgG), IgM, and IgA classes against TB in the serum of blood donors in Nice, France. If the number of individuals possessing IgG and IgA antibodies is present in reduced amounts, the IgM antibodies are detectable in a great number of donors, betraying fleeting incipient infections that will be disposed of quietly, without symptoms [ Figure 1 ].
Kaustova confirmed this observation by analyzing the serum of cancer patients: Antigen 60 (A60) IgG seropositivity was restricted to only some cancer forms, [9] and follow-up of patients indicated that seropositivity revealed a true mycobacterial disease, unapparent upon first evaluation. Mycobacterial infections, not necessarily TB, are also frequent in HIV positives, which are now universally accepted, but also in cancerous children [10] and transplant patients. [11] 10-fold discrepancy was suggestive of a variable toxicity of different BCG strains, which will be discussed infra.
India
The WHO and UNICEF provided support for a BCG vaccine production center in Guindy, Madras/ Chennai, in 1948.
Vaccination was extended to schools in almost all states of India in 1949. In 1950, Dr. P. V. Benjamin reported that TB infection was so widespread that no part of the country was free from it. Indian villagers were vaccinated in 1950, who showed an excess of 90% of TB cases. [19] To salvage the BCG, a committee appointed jointly by the Indian Council of Medical Research (ICMR) and the WHO acknowledged that the BCG is powerless against lung TB but that it provided substantial protection against childhood forms of TB such as tubercular meningitis and miliary TB; it recommended to give the vaccine before the end of the 1 st year after birth. The possibility of a variability of activity of BCG according to strain was not envisaged.
The French Empire and Libya
A vaccination trial was organized in Algeria in 1935, whose results concerning the general infantile morality were tooted superior to the results obtained by Calmette in France. [20] The vaccination of the population of the French Empire and of Libya was started in 1950. Its efficacy was not verified, but local public health officers reported excess TB cases among the vaccines. In 1978, Henry Quiquendon divulged that the WHO had observed an excess of TB cases among vaccinees in Finland and Denmark, well ahead of its endorsement of the vaccine. [15] 
Proof of protection based on tuberculin allergy
Calmette observed in 1928 that, 2 years after the vaccination, only 28% of the vaccinees confined in a protected environment reacted on an intradermal tuberculin injection. The first Congress of BCG was held June 18, 1948 . It claimed unanimously (with Ferru's abstention) that BCG provokes within a short time (48-72 h) a neat and lasting allergy detected by tuberculin. A second vaccination was recommended if the first one had not elicited a positive tuberculin reaction.
The congressional representatives neglected the observation made by Calmette in 1928. The skin allergy induced by a BCG inoculation was found in 1999 in Saudi Arabia to be of the order of 7.8%, 5 years after vaccination. An Italian study performed at the same time [21] attributed a skin induration superior to 11 mm in vaccinated individuals not to BCG but to a tuberculous infection. The BCG does not or only rarely induce a DTH reaction, and the indurations >11 mm observed in vaccinees are due to unapparent TB infections. Comstock observed that vaccinees responded to a tuberculin skin test either not at all or else with a skin induration like the one obtained with TB patients. He also observed that the positive response was obtained mainly among vaccinated former TB patients. [22] These proofs that the reactivity to tuberculin following a BCG vaccination was not due to the vaccine but to a TB or other mycobacterial unapparent infections were corroborated by a Swedish study analyzing the sensitivity to tuberculin of vaccinated and nonvaccinated children. [23] Three percent of the nonvaccinated controls were tuberculin reactive versus 49% of the vaccinated children. The children in Sweden spend the winter months at home, caring for pet animals (birds and fishes). The Swedish investigators controlled the skin reactivity of their individuals not only with tuberculin but also with avianin and scrofulascein, which would indicate infections with Mycobacterium avium and Mycobacterium scrofulaceum mycobacteria that infect birds and fishes. They found that 58% of the vaccinated children reacted to scrofulascein and 67% to avianin, while the frequencies found with these two sensitins in nonvaccinated children were only 25% for scrofulascein and 32% for avianin. The investigators concluded that BCG favored unapparent infections by atypical mycobacteria but refused to extend this obvious conclusion to TB.
The recommendation to revaccinate people who had remained inert to a previous vaccination was a sure way to infect them with TB.
Controlled clinical trials Leprosy
The promotion of leprosy by BCG was published in 1960 [24] and again twice in the nineties. [25, 26] A 9-fold excess of leprosy cases which affected only vaccinees <5 years was observed in 1989 in New Guinea, a TB-free zone, during the first 5 years following BCG vaccination. [27] These warnings were all ignored, and the newspaper "The Hindu" of January 29, 2017, announced: "Why India needs to step up its fight: In 2015, the country accounted for 60% of new cases of leprosy globally."
Tuberculosis Asia
Warning that the vaccination with BCG was iatrogenic was given by Frimodt-Moller in 1978. [19] A crushing observation by Tripathy in 1986 was that the vaccination applied to 260,000 Indians in 1970 (the Chingleput trial) resulted after a year in a 100% excess of symptomatic TB among the vaccinees. Four years after vaccination, the excess in symptomatic cases was 150%. [28] A study made in Iran reported in 1996 that the adjusted effectiveness of BCG vaccination of adults in the protection of pulmonary TB was −0.37 (95% confidence intervals: −1.66-0.31), indicating that the BCG sometimes favors transmission. [29] France The regression of the tuberculosis endemy grinded to a halt in France in 1987, followed by a 7% increase of TB cases in 1992 versus 1991. Grosset mentioned 10,000 new cases in 1994 in France and concluded that the fight against TB was a total failure. [30] Brazil The Proceedings of the National Academy of Sciences of the United States of America published in 1997 that the epidemic of TB occurring after the vaccination of the Yanomamo Amazonian tribe with BCG in 1994 was due to its immunological naivety. [31] However, the first case of TB among the Yanomami was observed 29 years previously, in 1965, with more cases appearing in the 1970s. The population was vaccinated in 1994 because TB cases were uncovered among its members. The population was exposed to TB a long time before the vaccination took place and the TB patients present in its midst did not cause an epidemic. The result of the vaccination was that 82% of the vaccinated population contracted TB. The epidemiological proof that the origin of the epidemic was the vaccine is indisputable. The BCG vaccination of the Brazilian indigenous population proceeded further, with some villages showing an average incidence in the period 1991-2002 that was 2500 per 100000, almost 50 times higher than the regional average, with about half the cases diagnosed in children <15 years. [32] The protection lend by the Bacillus Calmette-Guerin to children and to severe forms of the disease To justify its continued use in India, the ICMR and the WHO claimed in 1950 a protection given by the vaccine to children and its usefulness in severe forms of the disease, essentially tuberculous meningitis.
Children
In Hong Kong, a vaccination campaign was started in 1954. It claimed a reduction of infant TB mortality rate from 100% to 0% within 16 years. Figure 2 , taken from Wong and Oppenheimer study, [33] gives the results. What is misleading in this graph is the evolution of the infant TB mortality rate. Hidden is the fact that infant TB mortality rate had decreased by 40% within 2 years that preceded the vaccination campaign, as shown in Figure 3 .
Tuberculous meningitis
The proof of occasional infectiousness of BCG for meninges was given in France in 1927 [14] and restated in 1988. [34] It was negated in France in 1991 [35] but confirmed in Iran in 1999. [36] In this study of 100 children suffering from meningitis, only 10% responded to a tuberculin test, which indicates an immunosuppression, and only 22% were meninges-smear positive, which is the percentage defined as usual and normal for bacterioscopy by Mioerner in 1996. [37] Of the 30 children with a history of vaccination, 9/30 died (30%) versus 20/70 (28.6%) among the nonvaccinated children. These percentages of mortality are very similar.
The serological proof of inefficiency of infants' vaccination by the Bacillus Calmette-Guerin Failure by Bacillus Calmette-Guerin to generate antibodies against antigen 60
At the hospital of Necker-Enfants Malades, Paris, France, non-BCG vaccinated infants less than 2 years old were compared to BCG-vaccinated infants less than and older than 5 years for IgG antibodies' production against A60. A60 is an immunodominant protein antigen located inside the bacterium, not at its surface. The BCG failed to produce antibodies against its A60. [38] No IgG antibodies were detected in the nonvaccinated group, as was expected, but antibodies in the two vaccinated groups were also absent, with respectively two very weakly positive cases and one case barely emerging above the cutoff line [ Figure 4 ]. Considering the considerable extent of unapparent fleeting infections by TB [ Figure 1 ], these borderline-positive cases may be traced to increased exposure of the children to contacts outside the home (i.e., nursery, kindergarten, and kissing and hugging relatives).
Comparison of production by newborns of antibodies against antigen 60 and purified protein derivative (PPD)
An analysis of the humoral immune response induced after BCG vaccination of newborns monitored to produce IgG and IgM antibodies against PPD and A60 for 3 years was done in Ankara. [39] PPD contains an array of antigens among which LAM, a mycobacterial factor of virulence, while A60 is a dominant thermostable macromolecular antigen (TMA) factor of protection.
[40] Figure 5 shows that, at birth, a considerable number of infants had received passively from their mothers, IgG antibodies against the factor of protection A60, as well as against PPD. The study was performed in Ankara, and the possibility of latent TB infections in about 50% of the mothers, who would have IgG antibodies, is by no means an irrational hypothesis. IgM antibodies against A60 and PPD, which do not cross the placental barrier, were of course absent in the serum of newborns. At birth, about half of the babies were thus passively protected by maternal IgG antibodies, which disappeared 2-4 months after birth, despite the inoculation of the BCG vaccine. There was virtually no production of IgG antibodies against either A60 or PPD during the first 4 months following vaccination, and these rose only timidly thereafter. Fifteen months after vaccination, all the children, without any exception, began to produce large amounts of IgM antibodies against PPD. Fewer children produced in the meantime IgM antibodies against the factor of protection (A60). This large number of IgM antibodies against PPD versus IgM antibodies against A60 [ Figure 1 ] indicates that the evaluation of transient fleeting TB infections is largely underestimated.
Phenotype variations of Bacillus Calmette-Guerin
The failure of rabbit antibodies against TB to protect rabbits passively against an aerobic TB challenge was reported in 1974. [41] This observation does in no way inform about humoral protective antibodies synthetized during a human infection, yet it comforted the conclusion drawn from research of development of a serological test, ill-conducted in the absence of any biological understanding, [42] that antibodies play no significant role in the host's immune defense against mycobacterial infections, and all immunological protections continue to be traced in 2019 to the cellular immunity evidenced by a skin test. [43] Applying to BCG the flow-through method described supra for the detection of wild strains, we found that antibodies against BCG play as great a role in protection as cellular immunity. [8] a. In Table 4 The A60 antigen and the cytoplasm antigen were obtained by cell disruption and, in the case of the A60 complex, chromatographic isolation by standard methods. [44] 2. The antibodies used to label the cells and the antigens trapped on the membrane were:
• Rabbit antibodies against inactivated freeze-dried M. tuberculosis strain H37Ra (Difco 231141) • Rabbit antibodies against A60 of BCG PIB • Rabbit antibodies against a whole sonicate of the Copenhagen strain of BCG (Dako, Denmark)
This Table 4 reveals that the antibodies against whole H37Ra cells and the antibodies raised against the inner contents of the BCG obtained from the Pasteur Institute of Brabant (PIB) and from a Copenhagen strain, all three recognize very poorly whole BCG bacilli, but all three antibodies react well with cytoplasmic antigens.
b. Table 5 shows that an antiserum raised against a wild TB strain (whole cell) obtained from the Pasteur Institute of Tehran does barely react (±) with the cytoplasm of BCG PIB. Conversely, antiserum against the A60 of BCG PIB recognizes poorly (++/−) the cytoplasmic constituents of a wild TB strain c. Table 6 compares the interaction of three antibodies raised against A60-BCG strain Pasteur GL-2, against BCG sonicate strain Copenhagen, and against the whole cells of a wild strain obtained in Tehran, with the whole cells and the dissolved cells of a pathogenic TB strain and three BCG strains. Clearly, BCG Aventis differs from BCG Pasteur GL-2 and from BCG Copenhagen.
conclusIon
These data indicate that BCG induces the production of antibodies mainly against antigens only exposed when bacterial cells are lysed and thus when the infection is well established. I will show infra that the BCG vaccine elicits a vigorous cellular immune response, slow to shape and not detected by a skin test, which prevents proliferation. We therewith provide a simple explanation why BCG does not protect against infection but prevents dissemination from the primary foci to other parts of the body. The absence of creation of antibodies against the outer cell membrane of wild strains also explains the long persistence of the pathogen in the invaded host. The data further indicate that geographical variations in antigens observed among M. tuberculosis strains may be the cause of the discrepant results found when BCG efficacy is analyzed in different parts of the world. In addition, the outer cell membrane of BCG presents a phenotype variation according to strain. The efficacy of some BCG strains to synthesize antibodies against surface antigens of some pathogenic strains is therewith further compromised.
Immunotherapy
The essential contribution of immunotherapeutic agents would be to assist chemicals powerless in the suppression of an established immunodepressive infection. However, Tables 1 and 2 show that not all TB patients undergo an abrogation of their immune defenses inflicted either by the pathogen or else by the drugs used to eliminate the pathogen. The potential of the immunotherapeutic agent is masked in those patients whose chemotreatment is enough to restore their immune defenses and heal the patients. Two different types of immunotherapy may be applied.
Mycobacterium vaccae Success and failure of trials
Stanford et al. answered the TB challenge with Mycobacterium vaccae immunotherapy in 1994. [45] The proposed strategy elicited high expectations as well as violent rebuttals. Promising results were published in 1995, [46] but the study performed at Durban [47] in 1999 ruined the project. This study's purpose was to shorten a short-course anti-TB chemotherapy further, by the addition of killed M. vaccae at the start of the short-course anti-TB chemotherapy applied, which would accentuate the decrease in time needed to achieve a negative sputum culture. The conclusion was that M. vaccae immunotherapy has no benefit when added at the start of a presumably successful anti-TB chemotherapy. This outcome was evident. A single inoculation of killed M. vaccae at the beginning of the chemotreatment of patients of whom all the controls not receiving the immunotherapy survived had an immediate effect so limited that M. vaccae immunotherapy was claimed mistakenly useless. The same erroneous approach was taken in the following two trials made in 2000 and 2002 with HIV-infected adults. [48, 49] Yet, proof of efficacy was given already in 1999 and was successful because the immunodepression of the patients was considered. When the agent was used repeatedly, i.e., injected intramuscular monthly for 6 months to chronic patients resistant to isoniazid, streptomycin, and rifampin, 9 of 24 cases were cured after 18-month follow-up versus 1 of 24 cases in the control group. [50] Mode of action of Mycobacterium vaccae M. vaccae is a saprophyte mycobacterium used as a killed preparation. It generates a humoral and a cellular immune response, both of which may prove beneficial.
Humoral immunity
a. Table 7 shows the interaction between four antimycobacterial antibodies and the whole cells of a pathogenic TB strain (Tehran) and the whole cells of M. vaccae. It shows [51] that antibodies against the induce an arthritic syndrome in rats, which betrays a cellular immunity. [52] This cellular immunity is not an allergic reaction as the hypersensitivity reaction induced by tuberculin, observable after 48-72 h, but takes at least 8 days and may appear only 17 days after the challenge, depending on the race of the animals. [53] The lysates of M. vaccae and M. bovis strain BCG Pasteur GL-2 as well as their isolated TMAs (A60) were emulsified in FIA and inoculated deep at the base of the tails of two rats. The treatment induces a swelling of the hind paws of the animals, which is a cellular immune reaction.
Most of the results, recorded from day 1 to day 23 of the experiment, were negative. The hind paws of all the inoculated rats remained unchanged until 8 days after inoculation. At later times, only the hind paws of one of the two animals inoculated with the lysate of M. bovis cells strain BCG Pasteur GL-2 swelled considerably on day 9-11. The swelling induced with A60 from BCG Pasteur GL-2 followed the same pattern in two rats, indicating that these two BCG inducers possessed about the same potency, far superior to that of the M. vaccae extracts, which induced no arthritic syndrome.
General conclusion
The potential of the M. vaccae immunotherapeutic agent, essentially the formation of antibodies interacting with surface and with cytoplasmic antigens of TB, is masked in those patients whose chemotreatment is amply sufficient to heal the patients and is manifest in patients where the drugs are either not available on a regular basis or unable to fight the progress of the disease. The very weak cellular immune reactivity of M. vaccae is overcome by repeat inoculations of the immunotherapeutic, which proved save.
Nitric oxide generated by uleine
The first line of defense against an invading pathogen is the production of the highly reactive nitric oxide (NO) by macrophages and other cells. Yet, the TB pathogen grows in macrophages and suppresses their synthesis of NO. In addition to a specific immunotherapy provided by M. vaccae, the unspecific boosting of the immune defenses of the organism by stimulation of NO production is a second way to assist recalcitrant cases. The antimicrobial properties of NO are well established since 1995. [54] It is synthesized by consumption of L-arginine and O 2 , with production of citrulline. Synthesis of NO in humans is more restricted than in other mammalian species as mice and rats, and this restriction largely avoids autotoxicity of NO. [55] Food supplements boosting the immune defenses of the organism by promoting the synthesis of NO through uleine [56] are available and cheap compared to drugs. They were shown innocuous [57] but efficacious against HIV-infected patients. [58] Since NO is active in vivo against M. tuberculosis, [54] the supplement should be active against TB. Table 9 records the healing effect of a food supplement based on uleine on HIV patients under a tri-therapy that was noneffective. The administered food supplement Para aspido 80 units was sometimes completed with cytokines and nucleic acids. One observes that the chemotreatment given between time -1 month and time 0, when the food supplement was added, did not favor a gain in weight; the gain was minimal and sometimes was a loss but improved 
conclusIon
The world population has recently enormously increased in size, of which a sizable amount has been impoverished in the West, where it lives in crowded shacks and is poorly fed or underfed, whereas in other parts of the world, it is still deprived of the most elementary means of a decent living as electricity, running water, flushing toilets, sewage disposal, and soap. The dismal living conditions inflicted to the poorest are currently enhanced by the climate change provoked by the richest. Both impoverished groups are subject to stresses generated by dispossession, hunger, social exclusion, and war. These derelict populations, constantly exposed to TB infections, immigrate in cities where the possibility of transmission is amplified by gatherings at sporting events, dancing halls, crowded buses, and other transport means or else supermarkets where they take refuge in winter. TB is an immunological chronic disease generated by poverty and unhealthy living conditions and is backed by the vaccine meant to combat it. An immunotherapy based on M. vaccae and a food supplement boosting the immune defenses of the organism by promoting the synthesis of NO through uleine are available but not used. [58] Financial support and sponsorship
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